Offtext
Detecting signs of neurodegenerative diseases in minutes instead of years —that’s what the neuroClues eyetracking technology can do.
At the CHwapi Hospital Center in Belgium, neurologist and rehabilitation specialist Dr. Thibault Warlop has been using the device for almost a year to measure abnormal eye movements, primarily in Parkinson’s patients.
Dr. Thibault
Neurologist/Rehabilitation Specialist
CHwapi
The main difference lies in the transition from, qualitative and subjective observation, to, objective and, quantitative measurement. So while the, traditional bedside tests follow my finger, for example, depend on the, clinician, visual inspection and neuro clues use,high speed sensors, with, high resolution spatial and temporal resolution, that is able to detect micro movements. That's it's impossible. Physically impossible, for a human to see.
And, unlike traditional eye, tracking system, neuro clues is built, for clinical practice. So, combining, medical grade hardware, standards, standardized protocols, high precision and also, quick, analysis.
So in short, neuro clues bridges the gap between high level, precision of research and, the, everyday clinical practice.
Offtext
Eye movements while tracking specific shapes are recorded within 10 to 15 minutes. The recordings can be viewed immediately and, most importantly, repeatedly, allowing for the assessment of data. Depending on the pattern, Dr. Warlop can determine with much greater certainty whether the movements deviate from the norm.
The device is practical for everyday clinical use: It is lightweight and portable, and as a plug-and-play solution, easy to use.
The technology can achieve much for Parkinson patients.
Luca Matarazzo
Business Develoment & Distributor Manager
neuroClues
We have data that shows that, more or less 20%, 1 in 5 Parkinson diagnosed patients will have a misdiagnosis. We want to help, physicians and clinicians to be able to give that better differential diagnosis. Thanks to, our device, we want to help them, be able to give them a better, treatment option.
And we don't think that it's fair to tell people you live a very long life where you should be expecting, something completely different. So it's also a matter of, giving better communication to these patients throughout their treatment.
The neuroClues technology recently became ISO 27001 and CE certified. The startup is spreading its wings.
So we are, finally moving from a setting where it's a purely research company to a, company where we're actually finally, deploying our device to the, to the market
And we're growing more and more.
Offtext
Neurologist Warlop envisions a wide range of applications for the eye-tracking system in the future:
Warlop
The majority, of our patients are, patients suffering from Parkinson's, syndrome. but we can also use it, for, every movement disorder that we cannot explain, such as, young male, for example, with diplopia without any, ophthalmology pathology, for example.
We can also use it for Multiple sclerosis, his device will be used in new increasing, population pathological populations such as the brain injury, for example, and, and so on.
we are moving towards a more, objective quantitative, data driven, medicine and neuro clues, offers to us and to to to our patients, the possibility to detect, eye movement, abnormalities years earlier.
